BOSTON - BostonChron -- Andarix Pharmaceuticals, a clinical-stage biotechnology company pioneering targeted peptide therapies for rare cancers, today announced that CEO Chris Adams will present at the 3rd Targeted Radiopharmaceuticals (https://targeted-radiopharma-supplychain-manufa...) (TRP) Supply Chain & Manufacturing Summit in Boston on July 23-24, 2025. The invitation underscores growing industry recognition of Andarix's innovative approach to personalized cancer treatment.

Addressing Critical Unmet Need in Rare Cancers

Andarix is developing a proprietary platform that combines diagnostic imaging agents with targeted therapies to identify and treat patients with rare cancers. The company's technology leverages somatostatin peptide conjugates, which target receptors that are highly up-regulated on several solid tumors, including lung, pancreatic, and neuroendocrine cancers.

"Our dual approach—first identifying appropriate patients through imaging, then delivering targeted therapy—represents a significant advance in personalized oncology," said Chris Adams, CEO of Andarix Pharmaceuticals. "We're developing solutions for patient populations that have historically been underserved due to the challenges of rare disease clinical development."

More on Boston Chron

• Winzele: A Trusted Isolation Transformer Manufacturer
• Luxury Mediterranean Estate in Gotha Sells for $1.52 Million, Closing $45,000 Over Asking
• ZEELOOL's Black Friday Sale Starts Early with Up to 80% Off Frames
• UV Weathering Test Chamber vs Xenon Arc Test Chamber: What's the Right Solution for Your Products
• Emeritus Addresses Hospital Bed Shortages with Smart Storage Solutions

Clinical Progress and Market Opportunity

The company's lead products have successfully progressed through early clinical development, demonstrating the potential of the Andarix platform. The technology addresses cancers with significant unmet medical need:

• Neuroendocrine tumors: A rare but growing cancer diagnosis
• Pancreatic cancer: One of the deadliest forms of cancer with limited treatment options
• Lung cancer: The leading cause of cancer death worldwide, with certain subtypes amenable to targeted therapy

Strategic Focus on Clinical Excellence

Adams' presentation at the TRP Summit will focus on best practices for clinical trial execution in rare diseases, including early regulatory engagement, patient advocacy collaboration, and novel approaches to patient recruitment and retention—all critical factors for successful rare disease drug development.

The summit brings together industry leaders, clinical operations professionals, and patient advocacy groups to address the unique challenges of developing therapies for rare and complex diseases.

Investment Highlights

• Differentiated Technology Platform: Proprietary somatostatin peptide conjugates with broad applicability across multiple cancer types
• De-risked Clinical Development: Lead products have advanced through early clinical trials
• Personalized Medicine Approach: Companion diagnostic strategy enables precision patient selection
• Large Addressable Market: Targeting multiple cancer indications with significant unmet need
• Experienced Leadership: Management team with proven track record in oncology drug development

About Andarix Pharmaceuticals

More on Boston Chron

• Fulton County & Grow Your World Amplify Atlanta Youth Through the Youth Audio Collective
• 2026 Oscars Betting Odds: One Battle After Another Favored for Best Picture
• City of Boston and Northeastern University Announce New Five-Year PILOT Agreement and New Ten-Year Institutional Master Plan, which include Historic Commitments on Housing and Community Benefits
• Allen Field Co., Inc. Components Selected for Esko ArtiosCAD 3D Component Library
• Boston: Winners Announced For Icons of Franklin Park Poster Competition

Andarix Pharmaceuticals (https://d.docs.live.net/bcb37854b4868387/Desktop/https;/www.andarix.com) is at the forefront of personalized cancer therapy, developing both imaging agents for patient identification and targeted treatments for rare cancers. The company's proprietary platform is based on somatostatin peptide conjugates applicable to lung, pancreatic, neuroendocrine, and other cancers. Extensive research has validated that somatostatin receptors are highly up-regulated on several solid tumors, providing a therapeutic target for the company's innovative approach. For more information, visit www.andarix.com.

Investor Contact

Andarix Pharmaceuticals
617-957-9858
info@andarix.com